ArticleJournal of pharmacopuncture2026
Ethyl p-methoxycinnamate Exhibits Superior Multi-Modal Anti-Inflammatory Activity Compared to Structurally Related Cinnamic Acid Derivatives.
Article in Journal of pharmacopuncture, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to investigate the anti-inflammatory potential of cinnamic acid (CA) and its derivatives, ethyl p-methoxycinnamate (EPMC) and trans-4-methoxy cinnamic acid (APMC), using integrated in silico, Methods: Molecular docking was performed to evaluate binding interactions with inflammation-related proteins, including heat shock protein 90 alpha family class A member 1 (HSP90AA1), Janus kinase 2 (JAK2), prostaglandin-endoperoxide synthase 2 (PTGS2), lipoxygenase, heat shock protein 90 beta family class B member 1 (HSP90AB1), and nitric oxide synthase 3 (NOS3). Results: Molecular docking revealed that EPMC exhibited superior multi-target binding affinities across five inflammatory proteins compared with allyl p-methoxycinnamate (APMC) and CA, with notable interaction with prostaglandin-endoperoxide synthase 2 (PTGS2/COX-2) interaction (-6.29 kcal/mol). CA uniquely bound NOS3 (-3.06 kcal/mol), suggesting distinct mechanistic pathways. BSA denaturation assays demonstrated comparable IC50 values for EPMC (170.02 μg/mL), CA (171.48 μg/mL), and diclofenac sodium (165.05 μg/mL), whereas APMC exhibited weaker activity (215.06 μg/mL). Conclusion: EPMC demonstrates superior multi-modal anti-inflammatory activity through multi-target engagement and localized tissue action, positioning it as a promising lead for next-generation anti-inflammatory therapeutics with potentially improved safety profiles compared with conventional NSAIDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.